TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+16.47%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.4B
AUM Growth
+$1.4B
(+43%)
Cap. Flow
+$313M
Cap. Flow
% of AUM
22.32%
Top 10 Holdings %
Top 10 Hldgs %
35.88%
Holding
163
New
35
Increased
43
Reduced
14
Closed
8
Top Buys
| 1 |
Aurinia Pharmaceuticals
AUPH
|
$32.6M |
| 2 |
BioNTech
BNTX
|
$32.1M |
| 3 |
Relay Therapeutics
RLAY
|
$25.3M |
| 4 |
ITOS
iTeos Therapeutics
ITOS
|
$24.6M |
| 5 |
Immunocore
IMCR
|
$21.8M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$24.4M |
| 2 |
Dynavax Technologies
DVAX
|
$6.68M |
| 3 |
Beam Therapeutics
BEAM
|
$2.45M |
| 4 |
Inhibrx
INBX
|
$2.37M |
| 5 |
CRISPR Therapeutics
CRSP
|
$2.35M |
Sector Composition
| 1 | Healthcare | 95.59% |
| 2 | Technology | 1.47% |
| 3 | Communication Services | 1.22% |
| 4 | Real Estate | 0.34% |
| 5 | Financials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRNS
51
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $8.27M | 0.59% |
4,700,000
-100,000
| -2% | -$176K |
|
52
Liquidia Corp
LQDA
$2.52B
| $8M | 0.57% |
800,000
+450,000
| +129% | +$4.5M |
|
53
Design Therapeutics
DSGN
$339M
| $7.97M | 0.57% |
1,480,975
| – | – |
|
54
ALX Oncology
ALXO
$54.6M
| $7.65M | 0.55% |
+4,204,735
| New | +$7.65M |
|
55
Viking Therapeutics
VKTX
$3.02B
| $7.6M | 0.54% |
120,000
| – | – |
|
56
Insmed
INSM
$30.3B
| $7.3M | 0.52% |
100,000
| – | – |
|
57
Dianthus Therapeutics
DNTH
$781M
| $7.25M | 0.52% |
264,692
| – | – |
|
58
Biohaven
BHVN
$1.71B
| $7M | 0.5% |
140,000
| – | – |
|
59
Biogen
BIIB
$20.8B
| $6.78M | 0.48% |
35,000
| – | – |
|
60
Ventyx Biosciences
VTYX
$184M
| $6.76M | 0.48% |
3,100,000
| – | – |
|
61
Bausch + Lomb
BLCO
$5.18B
| $6.75M | 0.48% |
+350,000
| New | +$6.75M |
|
|
CNTA
62
Centessa Pharmaceuticals
CNTA
$2.13B
| $6.4M | 0.46% |
+400,000
| New | +$6.4M |
|
63
Structure Therapeutics
GPCR
$1.14B
| $6.34M | 0.45% |
144,500
| – | – |
|
64
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.08M | 0.43% |
800,000
| – | – |
|
65
Ionis Pharmaceuticals
IONS
$9.64B
| $6.01M | 0.43% |
150,000
| – | – |
|
66
AbCellera Biologics
ABCL
$1.19B
| $5.98M | 0.43% |
2,300,000
+1,838,301
| +398% | +$4.78M |
|
67
Black Diamond Therapeutics
BDTX
$164M
| $5.96M | 0.43% |
1,370,209
-232,991
| -15% | -$1.01M |
|
68
Apogee Therapeutics
APGE
$2.27B
| $5.87M | 0.42% |
100,000
| – | – |
|
|
OMIC
69
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $5.83M | 0.42% |
+372,000
| New | +$5.83M |
|
70
Precision BioSciences
DTIL
$59.5M
| $5.59M | 0.4% |
623,332
| – | – |
|
71
Lantheus
LNTH
$3.75B
| $5.49M | 0.39% |
50,000
| – | – |
|
72
Cytokinetics
CYTK
$5.98B
| $5.28M | 0.38% |
100,000
| – | – |
|
73
Nuvalent
NUVL
$5.74B
| $5.12M | 0.37% |
+50,000
| New | +$5.12M |
|
|
OKUR
74
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $5.01M | 0.36% |
2,946,260
-50,000
| -2% | -$85K |
|
75
Merus
MRUS
$5.04B
| $5M | 0.36% |
100,000
| – | – |
|